| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 7, 2026 | ±2.4% | -1.6% | over-priced |
| November 7, 2025 | ±3.2% | -3.7% | under-priced |
| August 7, 2025 | ±2.1% | +0.0% | over-priced |
| May 7, 2025 | ±3.3% | +1.0% | over-priced |
| November 12, 2024 | ±3.2% | -2.8% | over-priced |
| August 8, 2024 | ±2.6% | +2.1% | over-priced |
| May 8, 2024 | ±1.6% | -0.8% | over-priced |
| November 7, 2023 | ±1.8% | -0.7% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $1.61 | $7.0B | $2.0B |
| Q4 FY2025 | $1.74 | $7.9B | $2.2B |
| Q3 FY2025 | $2.43 | $7.8B | $3.1B |
| Q2 FY2025 | $1.56 | $7.1B | $2.0B |
Gilead Sciences Inc (GILD) reports in 98 days, with the next report estimated for September 19, 2026. Across the last 8 reports, options priced an average ±2.5% earnings move while the stock actually moved 1.6% on average — the market has systematically over-priced GILD's earnings risk. Fundamentals into the print: EPS up 54.8% year-over-year, revenue up 4.4%. QuantLogix's live 5-factor engine currently reads GILD as a buy at 53/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →